RUNX3 belongs to the RUNX family of transcription factors, DNA-binding proteins that orchestrate the expression of large networks of genes by attaching to specific promoter and enhancer sequences. In healthy tissue, RUNX3 is intimately involved in cell differentiation, immune cell development, and the suppression of abnormal growth. In many tumors, however, the gene is silenced through mechanisms such as promoter hypermethylation, in which methyl groups are added to the DNA region controlling RUNX3 expression, effectively switching the gene off without altering its sequence. The loss of RUNX3 function removes a natural brake on cell proliferation, allowing tumor cells to divide unchecked, evade programmed cell death, and acquire invasive properties. The new review emphasizes that this same loss also appears to blunt the sensitivity of cancer cells to chemotherapeutic agents.

The mechanistic breadth of RUNX3’s influence on chemosensitivity is striking. According to the review, RUNX3 modulates at least seven interconnected processes that govern drug response: apoptosis, drug efflux, cell cycle dynamics, oxidative stress, cancer stem cell properties, epithelial-to-mesenchymal transition, and metabolic reprogramming. Each of these represents a well-documented route by which tumors develop resistance to treatment. When RUNX3 is functional, it promotes apoptosis, the controlled self-destruction of damaged cells, by influencing key regulators of the intrinsic death pathway. This means that in RUNX3-proficient tumors, chemotherapy-induced DNA damage is more likely to trigger the cellular suicide program that drugs such as platinum agents and taxanes rely upon to kill malignant cells.

Drug efflux is another arena in which RUNX3 exerts considerable power. Chemotherapy frequently fails because tumor cells overexpress ATP-binding cassette transporters, membrane pumps that expel cytotoxic drugs before they can accumulate to lethal concentrations. The review details evidence that RUNX3 can suppress the expression of these efflux pumps, thereby keeping drug concentrations inside cancer cells high enough to be effective. Conversely, when RUNX3 is lost or silenced, efflux machinery ramps up, and drugs are pumped out almost as quickly as they enter. This single regulatory relationship helps explain why patients with epigenetically silenced RUNX3 often respond poorly to standard regimens, and why restoring RUNX3 expression could resensitize tumors to agents they had previously resisted.

Cell cycle control adds a further layer of complexity. Many chemotherapeutics are most effective against rapidly dividing cells, because they target DNA replication or mitosis. RUNX3 helps enforce checkpoint controls that can either halt division in damaged cells or push them toward death. The review describes how RUNX3 interacts with cyclin-dependent kinase inhibitors and other cell cycle regulators to modulate the pace of proliferation. In tumors where RUNX3 is absent, cells may accumulate in phases of the cell cycle that render them less vulnerable to phase-specific drugs, a phenomenon known as quiescence-associated resistance. Reinstating RUNX3 activity could therefore reposition tumor cells in phases of the cycle where chemotherapy is most lethal.

Perhaps the most clinically provocative section of the review concerns cancer stem cells and epithelial-to-mesenchymal transition. Cancer stem cells are a small subpopulation of tumor cells with the capacity for self-renewal and the ability to seed new tumors. They are notoriously resistant to conventional chemotherapy and are widely believed to be responsible for relapse after seemingly successful treatment. EMT, meanwhile, is the process by which epithelial cancer cells acquire motile, mesenchymal characteristics, enhancing invasion and metastasis while simultaneously increasing drug tolerance. The review marshals evidence that RUNX3 suppresses both programs. By restraining EMT-associated transcription factors and limiting stem-like properties, RUNX3 reduces the pool of drug-tolerant cells within a tumor. Its loss permits the expansion of these resilient populations, setting the stage for treatment failure and disease recurrence.

Metabolic reprogramming and oxidative stress responses round out the mechanistic picture. Cancer cells rewire their metabolism to favor survival under harsh conditions, shifting toward glycolysis, altering mitochondrial function, and mounting robust antioxidant defenses that neutralize the reactive oxygen species generated by many chemotherapeutic drugs. The review indicates that RUNX3 influences these metabolic pathways, potentially tipping the balance back toward drug-induced oxidative damage. In RUNX3-deficient tumors, enhanced antioxidant capacity and metabolic flexibility allow cells to withstand the biochemical assault of treatment. This suggests that combining RUNX3 restoration with standard chemotherapy could amplify the lethal effects of treatment while simultaneously closing off the escape routes tumors typically use to survive.

Beyond its mechanistic roles, the review positions RUNX3 as a candidate biomarker for predicting chemotherapy response. Because RUNX3 silencing is often detectable through methylation assays or expression profiling of tumor biopsies, clinicians could conceivably use RUNX3 status to stratify patients before treatment begins. Those with intact RUNX3 expression might be expected to respond well to standard regimens, while those with silenced RUNX3 could be flagged for intensified therapy, epigenetic priming, or enrollment in trials of RUNX3-targeted interventions. The authors argue that this predictive capacity, combined with the molecule’s mechanistic centrality, makes RUNX3 a promising therapeutic target in its own right. Strategies to modulate RUNX3 include demethylating agents that reactivate the silenced gene, small molecules or gene therapy approaches that boost its expression, and drugs that mimic its downstream effects on apoptosis and efflux pathways.

The therapeutic opportunities are significant but come with caveats that the review acknowledges. RUNX3 is a transcription factor, and transcription factors have historically been considered difficult drug targets because they lack the enzymatic pockets that small-molecule inhibitors typically exploit. Restoring a tumor suppressor, rather than inhibiting an oncogene, also presents unique pharmacological challenges. Nevertheless, advances in epigenetic therapy, targeted gene delivery, and the development of molecules that stabilize or enhance transcription factor complexes are steadily eroding these barriers. The review suggests that combination approaches, in which RUNX3 restoration is paired with conventional chemotherapy or epigenetic drugs, may offer the most realistic near-term path to clinical benefit, resensitizing resistant tumors and extending the useful lifespan of existing drug regimens.

As chemoresistance remains a leading cause of cancer-related mortality worldwide, the identification of actionable regulators like RUNX3 carries substantial clinical weight. The synthesis presented in Cancer Cell International consolidates a decade of scattered findings into a coherent framework, positioning RUNX3 not merely as a passive marker of poor prognosis but as an active, manipulable node in the resistance machinery of tumors. If ongoing and future studies can translate RUNX3 modulation into safe and effective clinical interventions, oncologists may gain a powerful new tool for predicting treatment response and for converting resistant cancers back into treatable ones. For patients facing the devastating diagnosis of chemotherapy-resistant disease, that possibility represents a genuinely hopeful frontier in cancer research.

Subject of Research: The role of the RUNX3 transcription factor in regulating cancer chemoresistance and its potential as a therapeutic target and biomarker

Article Title: The role of RUNX3 in cancer chemoresistance: regulation and therapeutic opportunities

Article References: Gong, Y., Deng, H., Liao, X., & Zhang, J. (2026). The role of RUNX3 in cancer chemoresistance: regulation and therapeutic opportunities. Cancer Cell International. https://doi.org/10.1186/s12935-026-04460-7

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04460-7

Keywords: RUNX3, chemoresistance, cancer, transcription factor, tumor suppressor, apoptosis, drug efflux, epithelial-to-mesenchymal transition, cancer stem cells, metabolic reprogramming, biomarker, therapeutic target

The research, conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences (CHCAMS), delved into the complex milieu of cytokines—small proteins crucial for cell signaling and immune responses—to pinpoint factors associated with clinical benefit. Using an innovative flow fluorescence technique, the investigators analyzed an extensive panel of 41 cytokines in a discovery cohort comprising 42 aNSCLC patients treated with ICIs. Their goal was to discern molecular differences between those who experienced durable clinical benefit (DCB) and those who did not (NDB).

Remarkably, seven cytokines emerged as differentially expressed between these two cohorts, with CD14, CCL27, IL-17A, and TNFR1 being significantly elevated in patients who achieved durable responses. Conversely, EGF, CHI3L1, and CCL5 were found increased in patients with no durable benefit. Among these, the soluble form of CD14 stood out due to its impressive predictive performance, boasting an area under the curve (AUC) of 0.84—a robust metric indicating high accuracy in forecasting clinical outcomes.

Further in-depth analyses showed that sCD14 is intrinsically linked to pivotal immune pathways that orchestrate the body’s defense against tumors. Functional enrichment studies revealed connections to the inflammatory response and the MAPK signaling pathway, underscoring the protein’s multifaceted role in modulating immune activity and potentially enhancing the effectiveness of immunotherapy. This insight is especially critical given that immune evasion mechanisms remain a major hurdle in cancer treatment.

The prognostic value of sCD14 was not merely a statistical artifact confined to the discovery group. Validation cohorts—including 109 patients with plasma protein measurements, 22 patients assessed via multiplex immunofluorescence (mIF), and an expansive cohort of 403 NSCLC patients analyzed through messenger RNA datasets—consistently confirmed that elevated sCD14 correlates with prolonged progression-free survival (PFS). This consistent trend across diverse methodologies and independent datasets, such as GSE126044 and GSE135222, strongly supports the robustness and reproducibility of sCD14 as a biomarker.

Interestingly, the study also revealed that CD14 expression is elevated not only within tumor environments but also in various normal tissues, particularly lung adenocarcinoma and lung squamous cell carcinoma. This pattern hints at sCD14’s potential involvement in immune surveillance, signifying a broader, systemic role in maintaining immune vigilance beyond tumor confines. Such a finding opens doors to novel therapeutic strategies that might harness or enhance this natural defense mechanism.

From a mechanistic perspective, CD14 functions as a co-receptor for toll-like receptors (TLRs), particularly TLR4, which are critical for recognizing pathogen-associated molecular patterns and triggering immune responses. In the context of cancer, this TLR-CD14 axis may activate inflammatory pathways that promote antitumor immunity, facilitating immune cell infiltration and activity within the tumor microenvironment—essential factors for effective immunotherapy.

Beyond its biological role, the clinical implications of measuring plasma sCD14 are profound. A minimally invasive blood test capable of reliably predicting patient response to ICIs could revolutionize treatment paradigms, sparing non-responders from unnecessary side effects and healthcare costs while enabling a more personalized and adaptive therapeutic strategy. This aligns with the broader movement toward precision oncology, where biomarkers guide tailored interventions.

Despite these promising results, questions remain regarding the precise molecular cascades downstream of sCD14 that modulate immune dynamics in lung cancer. Furthermore, the interplay between sCD14 levels and other known prognostic factors, such as programmed death-ligand 1 (PD-L1) expression and tumor mutational burden, warrants comprehensive exploration. Future studies integrating these variables could refine predictive models and optimize patient stratification.

It is also worth noting that the study leveraged cutting-edge multiplex immunofluorescence, a powerful imaging technique that enables spatial mapping of multiple immune markers simultaneously within tissue samples. This allowed the researchers to not only quantify CD14 levels but also contextualize its expression within the intricate tumor-immune interface—an approach that provides richer insight than conventional methods.

Moreover, the robust association between elevated sCD14 and improved PFS challenges some conventional assumptions, as soluble immune mediators are often regarded solely as markers of inflammation or tumor burden. Here, sCD14 appears to signal an active, effective immune response, highlighting the nuanced role cytokines play in cancer immunity—a dualistic nature that continues to intrigue immunologists.

Taken together, the data position sCD14 as a compelling biomarker capable of bridging the gap between basic immunology research and clinical application. Its strong prognostic value, ease of measurement, and correlation with critical immune pathways make it a prime candidate for incorporation into future clinical trials and routine monitoring of aNSCLC patients undergoing immunotherapy.

This study represents a milestone in understanding the immune landscape of lung cancer and opens avenues for enhancing patient outcomes through biomarker-informed approaches. As immunotherapies continue to reshape oncology, integrating biomarkers like sCD14 could ensure that patients receive the most effective treatment regimens tailored to their unique immune profiles.

While further validation in larger, multiethnic cohorts and real-world settings will be necessary to cement sCD14’s clinical utility, the current findings provide a strong foundation for such efforts. Concurrently, mechanistic studies dissecting how sCD14 modulates the tumor microenvironment could identify novel therapeutic targets that synergize with checkpoint blockade.

In conclusion, the identification of pretreatment plasma sCD14 as a robust prognostic indicator heralds a new era of biomarker-driven immunotherapy in advanced non-small cell lung cancer. Its association with improved progression-free survival not only enhances our understanding of immune-tumor interactions but also paves the way for more personalized, effective cancer care paradigms centered on immune biomarkers.

The promise of sCD14 extends beyond prognostication, potentially informing combination therapies that amplify immune responses or mitigate immunotherapy resistance mechanisms. As researchers and clinicians continue to unravel the complexities of tumor immunity, discoveries like this offer hope for transforming lung cancer outcomes in the era of precision medicine.

Subject of Research: Prognostic biomarkers in advanced non-small cell lung cancer patients undergoing immunotherapy

Article Title: Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy

Article References:
Dai, L., Huang, L., Li, L. et al. Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy. BMC Cancer 25, 763 (2025). https://doi.org/10.1186/s12885-025-14148-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14148-2

Keywords: sCD14, non-small cell lung cancer, immunotherapy, prognostic biomarker, cytokines, immune checkpoint inhibitors, progression-free survival, tumor microenvironment